INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
New trends in the diagnosis of dry eye disease: A patient-centric approach
A five-step approach to personalise and simplify treatment, leading to higher efficacy
Higher Molar Dose and Its Translation into Clinical Practice
Industry updates and clinical trial data at the upcoming 2025 ARVO Annual Meeting
Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more
DMO study meta-analysis illuminates how racial subgroups are underrepresented in clinical trials
The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab
Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab
The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase
Clinicians may improve follow-up adherence by leveraging social media apps
Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis